Skip to main content
SpringerLink
Log in

Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics

  • Minireview
  • Published:
Journal of Microbiology Aims and scope Submit manuscript

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common types of liver diseases worldwide and its incidence continues to increase. NAFLD occurs when the body can no longer effectively store excess energy in the adipose tissue. Despite the increasing prevalence of NAFLD, making lifestyle changes, including increased exercise, is often an elusive goal for patients with NAFLD. The liver directly connects to the gut-gastrointestinal milieu via the portal vein, which are all part of the gut-liver axis. Therefore, the gut-microbiome and microbial products have been actively studied as likely key factors in NAFLD pathophysiology. Hence, dysbiosis of the gut microbiome and therapeutic manipulation of the gut-liver axis are being investigated. Novel therapeutic approaches for modulating gut microbiota through the administration of probiotics, prebiotics, synbiotics, and antibiotics have been proposed with numerous promising initial reports on the effectiveness and clinical applications of these approaches. This review delves into the current evidence on novel therapies that modulate gut microbiota and discusses ongoing clinical trials targeting the gut-liver axis for the management and prevention of NAFLD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abdelmalek, M.F., Suzuki, A., Guy, C., Unalp-Arida, A., Colvin, R., Johnson, R.J., Diehl, A.M., and Nonalcoholic Steatohepatitis Clinical Research Network. 2010. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 1961–1971.

    Article  PubMed  CAS  Google Scholar 

  • Alisi, A., Bedogni, G., Baviera, G., Giorgio, V., Porro, E., Paris, C., Giammaria, P., Reali, L., Anania, F., and Nobili, V. 2014. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 39, 1276–1285.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Aller, R., De Luis, D.A., Izaola, O., Conde, R., Gonzalez Sagrado, M., Primo, D., De La Fuente, B., and Gonzalez, J. 2011. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci. 15, 1090–1095.

    PubMed  CAS  Google Scholar 

  • Aranha, M.M., Cortez-Pinto, H., Costa, A., da Silva, I.B., Camilo, M.E., de Moura, M.C., and Rodrigues, C.M. 2008. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur. J. Gastroenterol. Hepatol. 20, 519–525.

    Article  PubMed  CAS  Google Scholar 

  • Bajaj, J.S., Heuman, D.M., Hylemon, P.B., Sanyal, A.J., Puri, P., Sterling, R.K., Luketic, V., Stravitz, R.T., Siddiqui, M.S., Fuchs, M., et al. 2014. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment. Pharmacol. Ther. 39, 1113–1125.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bajaj, J.S., Heuman, D.M., Wade, J.B., Gibson, D.P., Saeian, K., Wegelin, J.A., Hafeezullah, M., Bell, D.E., Sterling, R.K., Stravitz, R.T., et al. 2011. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140, 478–487.

    Article  PubMed  CAS  Google Scholar 

  • Bajaj, J.S., Idilman, R., Mabudian, L., Hood, M., Fagan, A., Turan, D., White, M.B., Karakaya, F., Wang, J., Atalay, R., et al. 2018. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort. Hepatology 68, 234–247.

    Article  PubMed  CAS  Google Scholar 

  • Bajaj, J.S., Ridlon, J.M., Hylemon, P.B., Thacker, L.R., Heuman, D.M., Smith, S., Sikaroodi, M., and Gillevet, P.M. 2012. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G168–G175.

    Article  PubMed  CAS  Google Scholar 

  • Bajaj, J.S. and Riggio, O. 2010. Drug therapy: Rifaximin. Hepatology 52, 1484–1488.

    Article  PubMed  CAS  Google Scholar 

  • Bergheim, I., Weber, S., Vos, M., Kramer, S., Volynets, V., Kaserouni, S., McClain, C.J., and Bischoff, S.C. 2008. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. J. Hepatol. 48, 983–992.

    Article  PubMed  CAS  Google Scholar 

  • Bilzer, M., Roggel, F., and Gerbes, A.L. 2006. Role of Kupffer cells in host defense and liver disease. Liver Int. 26, 1175–1186.

    Article  PubMed  CAS  Google Scholar 

  • Bindels, L.B., Porporato, P., Dewulf, E.M., Verrax, J., Neyrinck, A.M., Martin, J.C., Scott, K.P., Buc Calderon, P., Feron, O., Muccioli, G.G., et al. 2012. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br. J. Cancer 107, 1337–1344.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Boursier, J. and Diehl, A.M. 2015. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog. 11, e1004559.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo-Perez, F., Guy, C.D., Seed, P.C., Rawls, J.F., David, L.A., et al. 2016. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764–775.

    Article  PubMed  CAS  Google Scholar 

  • Brandl, K., Kumar, V., and Eckmann, L. 2017. Gut-liver axis at the frontier of host-microbial interactions. Am. J. Physiol. Gastrointest. Liver Physiol. 312, G413–G419.

    Article  PubMed  PubMed Central  Google Scholar 

  • Carr, R.M., Oranu, A., and Khungar, V. 2016. Nonalcoholic fatty liver disease: Pathophysiology and management. Gastroenterol. Clin. North Am. 45, 639–652.

    Article  PubMed  PubMed Central  Google Scholar 

  • Cassard, A.M. and Ciocan, D. 2018. Microbiota, a key player in alcoholic liver disease. Clin. Mol. Hepatol. 24, 100–107.

    Article  PubMed  Google Scholar 

  • Chassaing, B., Etienne-Mesmin, L., and Gewirtz, A.T. 2014. Microbiota- liver axis in hepatic disease. Hepatology 59, 328–339.

    Article  PubMed  CAS  Google Scholar 

  • Chavez-Tapia, N.N., Uribe, M., Ponciano-Rodriguez, G., Medina-Santillan, R., and Mendez-Sanchez, N. 2009. New insights into the pathophysiology of nonalcoholic fatty liver disease. Ann. Hepatol. 8 Suppl 1, S9–17.

    Article  PubMed  CAS  Google Scholar 

  • Chen, Y., Yang, F., Lu, H., Wang, B., Chen, Y., Lei, D., Wang, Y., Zhu, B., and Li, L. 2011. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54, 562–572.

    Article  PubMed  Google Scholar 

  • Compare, D., Coccoli, P., Rocco, A., Nardone, O.M., De Maria, S., Carteni, M., and Nardone, G. 2012. Gut–liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 22, 471–476.

    Article  PubMed  CAS  Google Scholar 

  • Cope, K., Risby, T., and Diehl, A.M. 2000. Increased gastrointestinal ethanol production in obese mice: Implications for fatty liver disease pathogenesis. Gastroenterology 119, 1340–1347.

    Article  PubMed  CAS  Google Scholar 

  • Csak, T., Velayudham, A., Hritz, I., Petrasek, J., Levin, I., Lippai, D., Catalano, D., Mandrekar, P., Dolganiuc, A., Kurt-Jones, E., et al. 2011. Deficiency in myeloid differentiation factor-2 and Toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G433–441.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Cui, X., Ye, L., Li, J., Jin, L., Wang, W., Li, S., Bao, M., Wu, S., Li, L., Geng, B., et al. 2018. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci. Rep. 8, 635.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • De Santis, A., Famularo, G., and De Simone, C. 2000. Probiotics for the hemodynamic alterations of patients with liver cirrhosis. Am. J. Gastroenterol. 95, 323–324.

    Article  PubMed  Google Scholar 

  • Del Chierico, F., Nobili, V., Vernocchi, P., Russo, A., Stefanis, C., Gnani, D., Furlanello, C., Zandona, A., Paci, P., Capuani, G., et al. 2017. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated metaomics- based approach. Hepatology 65, 451–464.

    Article  PubMed  CAS  Google Scholar 

  • Delzenne, N.M. and Kok, N. 2001. Effects of fructans-type prebiotics on lipid metabolism. Am. J. Clin. Nutr. 73, 456S–458S.

    Article  PubMed  CAS  Google Scholar 

  • Ding, S., Chi, M.M., Scull, B.P., Rigby, R., Schwerbrock, N.M., Magness, S., Jobin, C., and Lund, P.K. 2010. High-fat diet: Bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 5, e12191.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Dumas, M.E., Barton, R.H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J.C., et al. 2006. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl. Acad. Sci. USA 103, 12511–12516.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Eguchi, S., Takatsuki, M., Hidaka, M., Soyama, A., Ichikawa, T., and Kanematsu, T. 2011. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: A prospective randomized study. Am. J. Surg. 201, 498–502.

    Article  PubMed  Google Scholar 

  • Eslamparast, T., Poustchi, H., Zamani, F., Sharafkhah, M., Malekzadeh, R., and Hekmatdoost, A. 2014. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am. J. Clin. Nutr. 99, 535–542.

    Article  PubMed  CAS  Google Scholar 

  • Esposito, E., Iacono, A., Bianco, G., Autore, G., Cuzzocrea, S., Vajro, P., Canani, R.B., Calignano, A., Raso, G.M., and Meli, R. 2009. Probiotics reduce the inflammatory response induced by a highfat diet in the liver of young rats. J. Nutr. 139, 905–911.

    Article  PubMed  CAS  Google Scholar 

  • Etienne-Mesmin, L., Vijay-Kumar, M., Gewirtz, A.T., and Chassaing, B. 2016. Hepatocyte Toll-like receptor 5 promotes bacterial clearance and protects mice against high-fat diet-induced liver disease. Cell. Mol. Gastroenterol. Hepatol. 2, 584–604.

    Article  PubMed  PubMed Central  Google Scholar 

  • Famouri, F., Shariat, Z., Hashemipour, M., Keikha, M., and Kelishadi, R. 2017. Effects of probiotics on non-alcoholic fatty liver disease in obese children and adolescents: A randomized clinical trial. J. Pediatr. Gastroenterol. Nutr. 64, 413–417.

    Article  PubMed  CAS  Google Scholar 

  • Farhadi, A., Gundlapalli, S., Shaikh, M., Frantzides, C., Harrell, L., Kwasny, M.M., and Keshavarzian, A. 2008. Susceptibility to gut leakiness: A possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int. 28, 1026–1033.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gangarapu, V., Ince, A.T., Baysal, B., Kayar, Y., Kilic, U., Gok, O., Uysal, O., and Senturk, H. 2015. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 27, 840–845.

    Article  PubMed  CAS  Google Scholar 

  • Garcia-Martinez, I., Santoro, N., Chen, Y., Hoque, R., Ouyang, X., Caprio, S., Shlomchik, M.J., Coffman, R.L., Candia, A., and Mehal, W.Z. 2016. Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J. Clin. Invest. 126, 859–864.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gibson, G.R., Hutkins, R., Sanders, M.E., Prescott, S.L., Reimer, R.A., Salminen, S.J., Scott, K., Stanton, C., Swanson, K.S., Cani, P.D., et al. 2017. Expert consensus document: The international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 14, 491–502.

    Article  PubMed  Google Scholar 

  • Gonzalez, F.J., Jiang, C., and Patterson, A.D. 2016. An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology 151, 845–859.

    Article  PubMed  CAS  Google Scholar 

  • Gupta, A. and Khanna, S. 2017. Fecal microbiota transplantation. JAMA 318, 102.

    Article  PubMed  Google Scholar 

  • Hossain, N., Kanwar, P., and Mohanty, S.R. 2016. A comprehensive updated review of pharmaceutical and nonpharmaceutical treatment for NAFLD. Gastroenterol. Res. Pract. 2016, 7109270.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hutkins, R.W., Krumbeck, J.A., Bindels, L.B., Cani, P.D., Fahey, G. Jr., Goh, Y.J., Hamaker, B., Martens, E.C., Mills, D.A., Rastal, R.A., et al. 2016. Prebiotics: Why definitions matter. Curr. Opin. Biotechnol. 37, 1–7.

    Article  PubMed  CAS  Google Scholar 

  • Jernberg, C., Lofmark, S., Edlund, C., and Jansson, J.K. 2007. Longterm ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 1, 56–66.

    Article  PubMed  CAS  Google Scholar 

  • Jiang, W., Wu, N., Wang, X., Chi, Y., Zhang, Y., Qiu, X., Hu, Y., Li, J., and Liu, Y. 2015. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci. Rep. 5, 8096.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R.G., Krausz, K.W., Cai, J., Qi, Y., Fang, Z.Z., Takahashi, S., et al. 2015. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125, 386–402.

    Article  PubMed  Google Scholar 

  • Jirillo, E., Caccavo, D., Magrone, T., Piccigallo, E., Amati, L., Lembo, A., Kalis, C., and Gumenscheimer, M. 2002. The role of the liver in the response to LPS: Experimental and clinical findings. J. Endotoxin. Res. 8, 319–327.

    PubMed  CAS  Google Scholar 

  • Jones, B.V., Begley, M., Hill, C., Gahan, C.G., and Marchesi, J.R. 2008. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc. Natl. Acad. Sci. USA 105, 13580–13585.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kundu, P., Blacher, E., Elinav, E., and Pettersson, S. 2017. Our gut microbiome: The evolving inner self. Cell 171, 1481–1493.

    Article  PubMed  CAS  Google Scholar 

  • Lambert, J.E., Parnell, J.A., Eksteen, B., Raman, M., Bomhof, M.R., Rioux, K.P., Madsen, K.L., and Reimer, R.A. 2015. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: A randomized controlled trial protocol. BMC Gastroenterol. 15, 169.

    Article  PubMed  PubMed Central  Google Scholar 

  • Larsen, N., Vogensen, F.K., van den Berg, F.W., Nielsen, D.S., Andreasen, A.S., Pedersen, B.K., Al-Soud, W.A., Sorensen, S.J., Hansen, L.H., and Jakobsen, M. 2010. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5, e9085.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Letexier, D., Diraison, F., and Beylot, M. 2003. Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. Am. J. Clin. Nutr. 77, 559–564.

    Article  PubMed  CAS  Google Scholar 

  • Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P.A., Moser, A.B., Desimone, C., Song, X.Y., and Diehl, A.M. 2003. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37, 343–350.

    Article  PubMed  CAS  Google Scholar 

  • Lindheim, L., Bashir, M., Munzker, J., Trummer, C., Zachhuber, V., Leber, B., Horvath, A., Pieber, T.R., Gorkiewicz, G., Stadlbauer, V., et al. 2017. Alterations in gut microbiome composition and barrier function are associated with reproductive and metabolic defects in women with polycystic ovary syndrome (PCOS): A pilot study. PLoS One 12, e0168390.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Llorente, C. and Schnabl, B. 2015. The gut microbiota and liver disease. Cell. Mol. Gastroenterol. Hepatol. 1, 275–284.

    Article  PubMed  PubMed Central  Google Scholar 

  • Loft, S., Sonne, J., Dossing, M., and Andreasen, P.B. 1987. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand. J. Gastroenterol. 22, 117–123.

    Article  PubMed  CAS  Google Scholar 

  • Loguercio, C., De Simone, T., Federico, A., Terracciano, F., Tuccillo, C., Di Chicco, M., and Carteni, M. 2002. Gut-liver axis: A new point of attack to treat chronic liver damage? Am. J. Gastroenterol. 97, 2144–2146.

    Google Scholar 

  • Lonardo, A., Byrne, C.D., Caldwell, S.H., Cortez-Pinto, H., and Targher, G. 2016. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 1388–1389.

    Article  PubMed  CAS  Google Scholar 

  • Lv, L.X., Hu, X.J., Qian, G.R., Zhang, H., Lu, H.F., Zheng, B.W., Jiang, L., and Li, L.J. 2014. Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 improves acute liver injury induced by D-galactosamine in rats. Appl. Microbiol. Biotechnol. 98, 5619–5632.

    Article  PubMed  CAS  Google Scholar 

  • Ma, X., Hua, J., and Li, Z. 2008. Probiotics improve high fat dietinduced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J. Hepatol. 49, 821–830.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Malaguarnera, M., Vacante, M., Antic, T., Giordano, M., Chisari, G., Acquaviva, R., Mastrojeni, S., Malaguarnera, G., Mistretta, A., Li Volti, G., et al. 2012. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 57, 545–553.

    Article  PubMed  Google Scholar 

  • Mas, A., Rodes, J., Sunyer, L., Rodrigo, L., Planas, R., Vargas, V., Castells, L., Rodriguez-Martinez, D., Fernandez-Rodriguez, C., Coll, I., et al. 2003. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. J. Hepatol. 38, 51–58.

    Article  PubMed  CAS  Google Scholar 

  • Mazzotti, A., Caletti, M.T., Sasdelli, A.S., Brodosi, L., and Marchesini, G. 2016. Pathophysiology of nonalcoholic fatty liver disease: Lifestyle-gut-gene interaction. Dig. Dis. 34 Suppl 1, 3–10.

    Article  PubMed  Google Scholar 

  • McCullough, A.J. 2004. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 8, 521–533.

    Article  PubMed  Google Scholar 

  • Mencarelli, A., Cipriani, S., Renga, B., Bruno, A., D’Amore, C., Distrutti, E., and Fiorucci, S. 2012. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One 7, e45425.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Miele, L., Marrone, G., Lauritano, C., Cefalo, C., Gasbarrini, A., Day, C., and Grieco, A. 2013. Gut-liver axis and microbiota in NAFLD: Insight pathophysiology for novel therapeutic target. Curr. Pharm. Des. 19, 5314–5324.

    Article  PubMed  CAS  Google Scholar 

  • Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Masciana, R., Forgione, A., Gabrieli, M.L., Perotti, G., et al. 2009. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877–1887.

    Article  PubMed  CAS  Google Scholar 

  • Mofidi, F., Poustchi, H., Yari, Z., Nourinayyer, B., Merat, S., Sharafkhah, M., Malekzadeh, R., and Hekmatdoost, A. 2017. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial. Br. J. Nutr. 117, 662–668.

    Article  PubMed  CAS  Google Scholar 

  • Mouzaki, M., Comelli, E.M., Arendt, B.M., Bonengel, J., Fung, S.K., Fischer, S.E., McGilvray, I.D., and Allard, J.P. 2013. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58, 120–127.

    Article  PubMed  CAS  Google Scholar 

  • Mykhal’chyshyn, H.P., Bodnar, P.M., and Kobyliak, N.M. 2013. Effect of probiotics on proinflammatory cytokines level in patients with type 2 diabetes and nonalcoholic fatty liver disease. Lik. Sprava 2, 56–62.

    Google Scholar 

  • Nagata, K., Suzuki, H., and Sakaguchi, S. 2007. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J. Toxicol. Sci. 32, 453–468.

    Article  PubMed  CAS  Google Scholar 

  • Nair, S., Cope, K., Risby, T.H., and Diehl, A.M. 2001. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96, 1200–1204.

    Article  PubMed  CAS  Google Scholar 

  • Okubo, H., Sakoda, H., Kushiyama, A., Fujishiro, M., Nakatsu, Y., Fukushima, T., Matsunaga, Y., Kamata, H., Asahara, T., Yoshida, Y., et al. 2013. Lactobacillus casei strain Shirota protects against nonalcoholic steatohepatitis development in a rodent model. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G911–918.

    Article  PubMed  CAS  Google Scholar 

  • Pendyala, S., Neff, L.M., Suarez-Farinas, M., and Holt, P.R. 2011. Diet-induced weight loss reduces colorectal inflammation: Implications for colorectal carcinogenesis. Am. J. Clin. Nutr. 93, 234–242.

    Article  PubMed  CAS  Google Scholar 

  • Pereg, D., Kotliroff, A., Gadoth, N., Hadary, R., Lishner, M., and Kitay-Cohen, Y. 2011. Probiotics for patients with compensated liver cirrhosis: A double-blind placebo-controlled study. Nutrition 27, 177–181.

    Article  PubMed  CAS  Google Scholar 

  • Pineiro, M., Asp, N.G., Reid, G., Macfarlane, S., Morelli, L., Brunser, O., and Tuohy, K. 2008. FAO technical meeting on prebiotics. J. Clin. Gastroenterol. 42 Suppl 3 Pt 2, S156–159.

    Article  PubMed  Google Scholar 

  • Pokusaeva, K., Fitzgerald, G.F., and van Sinderen, D. 2011. Carbohydrate metabolism in Bifidobacteria. Genes Nutr. 6, 285–306.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ponziani, F.R., Scaldaferri, F., Petito, V., Paroni Sterbini, F., Pecere, S., Lopetuso, L.R., Palladini, A., Gerardi, V., Masucci, L., Pompili, M., et al. 2016. The role of antibiotics in gut microbiota modulation: The eubiotic effects of Rifaximin. Dig. Dis. 34, 269–278.

    Article  PubMed  Google Scholar 

  • Raman, M., Ahmed, I., Gillevet, P.M., Probert, C.S., Ratcliffe, N.M., Smith, S., Greenwood, R., Sikaroodi, M., Lam, V., Crotty, P., et al. 2013. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 11, 868–875.

    Article  PubMed  CAS  Google Scholar 

  • Raso, G.M., Simeoli, R., Iacono, A., Santoro, A., Amero, P., Paciello, O., Russo, R., D’Agostino, G., Di Costanzo, M., Canani, R.B., et al. 2014. Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and Toll-like receptor expression in rats fed a high-fat diet. J. Nutr. Biochem. 25, 81–90.

    Article  PubMed  CAS  Google Scholar 

  • Rayes, N., Seehofer, D., Theruvath, T., Schiller, R.A., Langrehr, J.M., Jonas, S., Bengmark, S., and Neuhaus. P. 2005. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation–a randomized, double-blind trial. Am. J. Transplant. 5, 125–130.

    Article  PubMed  Google Scholar 

  • Ridlon, J.M., Kang, D.J., and Hylemon, P.B. 2006. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 47, 241–259.

    Article  PubMed  CAS  Google Scholar 

  • Rinella, M.E. 2015. Nonalcoholic fatty liver disease: A systematic review. JAMA 313, 2263–2273.

    Article  PubMed  CAS  Google Scholar 

  • Rinella, M. and Charlton, M. 2016. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology 64, 19–22.

    Article  PubMed  Google Scholar 

  • Ritze, Y., Bardos, G., Claus, A., Ehrmann, V., Bergheim, I., Schwiertz, A., and Bischoff, S.C. 2014. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS One 9, e80169.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Roberfroid, M., Gibson, G.R., Hoyles, L., McCartney, A.L., Rastall, R., Rowland, I., Wolvers, D., Watzl, B., Szajewska, H., Stahl, B., et al. 2010. Prebiotic effects: Metabolic and health benefits. Br. J. Nutr. 104 Suppl 2, S1–63.

    Article  PubMed  CAS  Google Scholar 

  • Ruiz, A.G., Casafont, F., Crespo, J., Cayon, A., Mayorga, M., Estebanez, A., Fernadez-Escalante, J.C., and Pons-Romero, F. 2007. Lipopolysaccharide-binding protein plasma levels and liver TNFalpha gene expression in obese patients: Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 17, 1374–1380.

    Article  PubMed  Google Scholar 

  • Russell, D.W. 2003. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137–174.

    Article  PubMed  CAS  Google Scholar 

  • Saez-Lara, M.J., Robles-Sanchez, C., Ruiz-Ojeda, F.J., Plaza-Diaz, J., and Gil, A. 2016. Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: A review of human clinical trials. Int. J. Mol. Sci. 17, 928.

    Article  PubMed Central  CAS  Google Scholar 

  • Sanchez, M., Darimont, C., Drapeau, V., Emady-Azar, S., Lepage, M., Rezzonico, E., Ngom-Bru, C., Berger, B., Philippe, L., Ammon-Zuffrey, C., et al. 2014. Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. Br. J. Nutr. 111, 1507–1519.

    Article  PubMed  CAS  Google Scholar 

  • Sanyal, A.J., Banas, C., Sargeant, C., Luketic, V.A., Sterling, R.K., Stravitz, R.T., Shiffman, M.L., Heuman, D., Coterrell, A., Fisher, R.A., et al. 2006. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43, 682–689.

    Article  PubMed  Google Scholar 

  • Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., Neuschwander-Tetri, B.A., Lavine, J.E., Tonascia, J., Unalp, A., et al. 2010. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Sayin, S.I., Wahlstrom, A., Felin, J., Jantti, S., Marschall, H.U., Bamberg, K., Angelin, B., Hyotylainen, T., Oresic, M., and Backhed, F. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225–235.

    Article  PubMed  CAS  Google Scholar 

  • Schnabl, B. and Brenner, D.A. 2014. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146, 1513–1524.

    Article  PubMed  CAS  Google Scholar 

  • Seto, W.K. and Yuen, M.F. 2017. Nonalcoholic fatty liver disease in Asia: Emerging perspectives. J. Gastroenterol. 52, 164–174.

    Article  PubMed  CAS  Google Scholar 

  • Shavakhi, A., Minakari, M., Firouzian, H., Assali, R., Hekmatdoost, A., and Ferns, G. 2013. Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: A double blind randomized clinical trial. Int. J. Prev. Med. 4, 531–537.

    PubMed  PubMed Central  Google Scholar 

  • Soh, S.E, Ong, D.Q., Gerez, I., Zhang, X., Chollate, P., Shek, L.P., Lee, B.W., and Aw, M. 2010. Effect of probiotic supplementation in the first 6 months of life on specific antibody responses to infant hepatitis B vaccination. Vaccine 28, 2577–2579.

    Article  PubMed  CAS  Google Scholar 

  • Sookoian, S. and Pirola, C.J. 2017. Genetic predisposition in nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 23, 1–12.

    Article  PubMed  PubMed Central  Google Scholar 

  • Strauss, E., Tramote, R., Silva, E.P., Caly, W.R., Honain, N.Z., Maffei, R.A., and de Sa, M.F. 1992. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 39, 542–545.

    PubMed  CAS  Google Scholar 

  • Suk, K.T., Kim, M.Y., and Baik, S.K. 2014. Alcoholic liver disease: Treatment. World J. Gastroenterol. 20, 12934–12944.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Tarantino, G. and Finelli, C. 2015. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbiol. 10, 889–902.

    Article  PubMed  CAS  Google Scholar 

  • Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., and Schoonjans, K. 2008. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7, 678–693.

    Article  PubMed  CAS  Google Scholar 

  • Turnbaugh, P.J., Hamady, M., Yatsunenko, T., Cantarel, B.L., Duncan, A., Ley, R.E., Sogin, M.L., Jones, W.J., Roe, B.A., Affourtit, J.P., et al. 2009. A core gut microbiome in obese and lean twins. Nature 457, 480–484.

    Article  PubMed  CAS  Google Scholar 

  • Vajro, P., Mandato, C., Licenziati, M.R., Franzese, A., Vitale, D.F., Lenta, S., Caropreso, M., Vallone, G., and Meli, R. 2011. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr. 52, 740–743.

    Article  PubMed  Google Scholar 

  • Verbeke, L., Farre, R., Verbinnen, B., Covens, K., Vanuytsel, T., Verhaegen, J., Komuta, M., Roskams, T., Chatterjee, S., Annaert, P., et al. 2015. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am. J. Pathol. 185, 409–419.

    Article  PubMed  CAS  Google Scholar 

  • Vindigni, S.M. and Surawicz, C.M. 2017. Fecal microbiota transplantation. Gastroenterol. Clin. North Am. 46, 171–185.

    Article  PubMed  Google Scholar 

  • Vrieze, A., Van Nood, E., Holleman, F., Salojarvi, J., Kootte, R.S., Bartelsman, J.F., Dallinga-Thie, G.M., Ackermans, M.T., Serlie, M.J., Oozeer, R., et al. 2012. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913–916.

    Article  PubMed  CAS  Google Scholar 

  • Wahlstrom, A., Sayin, S.I., Marschall, H.U., and Backhed, F. 2016. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50.

    Article  PubMed  CAS  Google Scholar 

  • Wang, B., Jiang, X., Cao, M., Ge, J., Bao, Q., Tang, L., Chen, Y., and Li, L. 2016. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci. Rep. 6, 32002.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., Feldstein, A.E., Britt, E.B., Fu, X., Chung, Y.M., et al. 2011. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wieland, A., Frank, D.N., Harnke, B., and Bambha, K. 2015. Systematic review: Microbial dysbiosis and nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 42, 1051–1063.

    Article  PubMed  CAS  Google Scholar 

  • Wiest, R., Albillos, A., Trauner, M., Bajaj, J.S., and Jalan, R. 2017. Targeting the gut-liver axis in liver disease. J. Hepatol. 67, 1084–1103.

    Article  PubMed  CAS  Google Scholar 

  • Wong, V.W., Tse, C.H., Lam, T.T., Wong, G.L., Chim, A.M., Chu, W.C., Yeung, D.K., Law, P.T., Kwan, H.S., Yu, J., et al. 2013. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis–a longitudinal study. PLoS One 8, e62885.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Woodhouse, C.A., Patel, V.C., Singanayagam, A., and Shawcross, D.L. 2018. Review article: The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment. Pharmacol. Ther. 47, 192–202.

    Article  PubMed  CAS  Google Scholar 

  • Wu, W.C., Zhao, W., and Li, S. 2008. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J. Gastroenterol. 14, 313–317.

    Article  PubMed  PubMed Central  Google Scholar 

  • Xie, G., Wang, X., Liu, P., Wei, R., Chen, W., Rajani, C., Hernandez, B.Y., Alegado, R., Dong, B., Li, D., et al. 2016. Distinctly altered gut microbiota in the progression of liver disease. Oncotarget 7, 19355–19366.

    PubMed  PubMed Central  Google Scholar 

  • Xu, R.Y., Wan, Y.P., Fang, Q.Y., Lu, W., and Cai, W. 2012. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J. Clin. Biochem. Nutr. 50, 72–77.

    Article  PubMed  CAS  Google Scholar 

  • Xue, L., He, J., Gao, N., Lu, X., Li, M., Wu, X., Liu, Z., Jin, Y., Liu, J., Xu, J., et al. 2017. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci. Rep. 7, 45176.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zhao, Y., Wu, J., Li, J.V., Zhou, N.Y., Tang, H., and Wang, Y. 2013. Gut microbiota composition modifies fecal metabolic profiles in mice. J. Proteome Res. 12, 2987–2999.

    Article  PubMed  CAS  Google Scholar 

  • Zhu, L., Baker, S.S., Gill, C., Liu, W., Alkhouri, R., Baker, R.D., and Gill, S.R. 2013. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 57, 601–609.

    Article  PubMed  CAS  Google Scholar 

  • Zhu, L., Baker, R.D., Zhu, R., and Baker, S.S. 2016. Gut microbiota produce alcohol and contribute to NAFLD. Gut 65, 1232.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally to this work.

Authors and Affiliations

  1. ChunLab, Inc., Seoul, 06725, Republic of Korea

    Min Seok Cho & Byung-Yong Kim

  2. Division of Gastroenterology and Hepatology, College of Medicine, Hallym University, Chuncheon, 24253, Republic of Korea

    Sang Yeol Kim & Ki Tae Suk

Authors
  1. Min Seok Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang Yeol Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ki Tae Suk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Byung-Yong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ki Tae Suk or Byung-Yong Kim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cho, M.S., Kim, S.Y., Suk, K.T. et al. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 56, 855–867 (2018). https://doi.org/10.1007/s12275-018-8346-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12275-018-8346-2

Keywords

Search

Navigation